---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-22-000079"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2022-09-14T23:59:59+00:00"
generated_at: "2026-06-23T09:47:50.701738+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Caladrius stockholders approve merger with Cend Therapeutics, 1:15 reverse split, name change to Lisata Therapeutics

## Summary
- Merger with Cend approved: 25,973,235 for, 2,912,622 against, 172,676 abstain.
- Reverse stock split at 1:15 ratio approved: 31,343,168 for, 7,665,240 against.
- Name change to Lisata Therapeutics approved: 34,861,858 for, 4,003,401 against.
- Merger close expected Sep 15, 2022; combined company to trade as LSTA on Nasdaq.
- Board set reverse split ratio at 1:15; effective Sep 14, 2022 at 5:00 PM ET.

## SEC filing metadata
- accession: 0000320017-22-000079
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2022-09-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.03, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001722000079/0000320017-22-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001722000079/clbs-20220913.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-22-000079
- JSON: https://secwatch.observer/filing/0000320017-22-000079.json
- Plain text: https://secwatch.observer/filing/0000320017-22-000079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.